December 9, 2024 11:15 AM EST
R&D
Pharma

Ab­b­Vie de­clares third Phase 3 Parkin­son’s win from Cerev­el takeover

Ayisha Sharma

News Reporter

There’s a sil­ver lin­ing for Ab­b­Vie on its close­ly-fol­lowed buy­out of Cerev­el: The phar­ma com­pa­ny re­port­ed Mon­day that its Parkin­son’s dis­ease can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Coave rais­es €32M Se­ries A de­spite be­ing two years away from the clin­ic

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

A service from the Financial Times